Antiangiogenic therapy and p53.
Browder
Timothy
T
Children's Hospital, Harvard Medical School, Boston, MA 02115, USA.
Folkman
Judah
J
Hahnfeldt
Philip
P
Heymach
John
J
Hlatky
Lynn
L
Kieran
Mark
M
Rogers
Michael S
MS
D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D000818:Animals; D016158:Genes, p53; D006133:Growth Substances / Q000378:metabolism; D006801:Humans; D051379:Mice; D009374:Neoplasms, Experimental / Q000098:blood supply / Q000188:drug therapy* / Q000235:genetics / Q000473:pathology; D009389:Neovascularization, Pathologic; D020794:Receptor Protein-Tyrosine Kinases / Q000276:immunology / Q000378:metabolism; D017978:Receptors, Growth Factor / Q000276:immunology / Q000378:metabolism; D040262:Receptors, Vascular Endothelial Growth Factor; D014407:Tumor Cells, Cultured
D020533:Angiogenesis Inhibitors; D006133:Growth Substances; D017978:Receptors, Growth Factor; D020794:Receptor Protein-Tyrosine Kinases; D040262:Receptors, Vascular Endothelial Growth Factor